The Cancer biomarker is used in identifying early stage cancers and helps in prognosis and treatment predictions. Increasing prevalence of cancer such as blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer across the globe is impacting the growth of the cancer biomarker market. According to the World Health Organization (WHO), in 2015, approximately 8.8 million people died due to cancer. Cancer is uncontrolled growth and spreading of abnormal cells. Increasing risk of cancer is associated with increasing age. Around 77% of all cancers are diagnosed in elder population and most cases of cancer occur in middle-aged adults or older population.
The global cancer biomarker market was valued at around USD 12,737 million in 2017 and is expected to register a CAGR of 16.2 % during forecast period, 2019–2026.
The global market of cancer biomarker market is segmented by type, cancer type, profiling technology, and application.
On the basis the type market is segmented into type, protein biomarker, genetic biomarker, and others.
Based on the cancer type, the cancer biomarker market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, non-hodgkin’s lymphoma, melanoma, leukemia, thyroid cancer, bladder cancer, kidney cancer, and other cancers. Breast cancer is expected to be leading segment owing to increasing prevalence of cancer across the globe.
On the basis of profiling technology the cancer biomarker market is segmented into omics technologies, genomics, proteomics, other omics technology, imaging technologies, ultrasound, CT, MRI, PET, mammography, immunoassays, cytogenetics, in situ hybridization, and other cytogenetics, bioinformatics. Omic technologies segment is expected to hold major share of cancer biomarker market.
Based on the application the cancer biomarker market is segmented into diagnostics, research, prognostics, risk assessment and other applications.
Geographically, global cancer biomarker market is divided into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America and Middle East & Africa (LAMEA).
North America is expected to dominate the global cancer biomarker market. Rising incidence of nonmelanoma skin cancer in U.S. is driving the growth of the market. For instance, as per skin care foundation, diagnosis and treatment of nonmelanoma skin cancers has increased by 77 % from 1994 to 2014.
Europe is expected to be the second leading region in the global cancer biomarker market. Rise in prevalence of different types of cancer is propelling the growth of the market on account of diagnostic purpose. High prevalence of breast cancer in U.K, over 55,000 women are diagnosed with breast cancer each year in the U.K.
Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period 2019–2026. Rise in government initiative for cancer is also supporting the growth of the market. As per American Cancer Society, the cancer burden is dominated by China in Asia pacific, and regional burden of cancer is projected to increase by 41% by 2025.
LAMEA is expected to witness sluggish growth in the global market during the forecast period. This is attributed to the poor healthcare infrastructure in Africa and slow growing economies. However, increasing government policies to reduce the number of cases is expected to support the growth of the market.
The cancer biomarkers market is dominated by major players including Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Abbott Laboratories, Qiagen N.V., Merck & Co., Becton Dickinson and Company, and Hologic.
Our report covers cancer biomarker market insights, focusing on recent development in the market in different region and development strategies of the companies. Moreover, following sections are specifically covered in the report.